Urate Transporters: Transforming the Face of Hyperuricemia and Gout

Becker, Michael A.; Simkin, Peter A.; Sørensen, Leif

doi:10.3899/jrheum.141019

Cited by 5 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previous ndings, we found that kaempferol could effectively reverse the abnormal protein expressions of GLUT9, ABCG2, OAT1 and OCT2 in kidneys of mice. In brief, the anti-hyperuricemia effect, at least in part, is achieved by regulating renal transporter expressions [49][50][51]. Dysregulation of renal transporters can lead to excessive accumulation of UA in the body, which may activate in ammation.…”

Section: Discussionmentioning

confidence: 99%

Kaempferol suppresses inflammation in mice suffering from both hyperuricemia and gouty arthritis through inhibiting NLRP3 inflammasome and NF-κB pathway

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

The co-occurrence of hyperuricemia and gouty arthritis is common in patients, yet a suitable animal model for this condition is lacking. In present study, a mice model combined hyperuricemia and gouty arthritis was established. Kaempferol, a flavonoid compound with anti-inflammatory and urate-lowering properties, was administered to mice in different dosages (25, 50, and 100 mg/kg). The levels of uric acid, creatinine, blood urea nitrogen and xanthine oxidase activity were measured, then kidney and joint ankle tissues were examined for pathological changes. The expressions of renal transporters, oxidative stress and inflammatory cytokines were detected. Furthermore, the anti-inflammatory mechanism of kaempferol was verified from NOD-like receptor protein 3 (NLRP3) inflammasome and nuclear factor kappa B (NF-κB) pathway. The results of histological analyses showed that kaempferol ameliorated the glomerular and renal tubular lesions and ankle arthritis inflammatory infiltration caused by hyperuricemia combined with gouty arthritis. Additionally, treatment with kaempferol effectively alleviated oxidative stress and decreased the levels of pro-inflammatory cytokines. The research confirmed that kidney and joint inflammation in hyperuricemia combined with gouty arthritis mice were alleviated by kaempferol via suppressing NLRP3 inflammasome and NF-κB pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Kaempferol suppresses inflammation in mice suffering from both hyperuricemia and gouty arthritis through inhibiting NLRP3 inflammasome and NF-κB pathway

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…To prevent this, it is recommended to use colchicine or NSAII for a period shorter than 6 months. Due to its potential toxic effects (myopathy or neuropathy) and the fact that it has no effect in preventing the sedimentation of uric acid, colchicine treatment is not indicated as the long-term prophylaxis (12). In the prospective, double-blind study conducted by Borstad et al (13), patients with chronic gout were given colchicine and a placebo drug to prevent an acute gouty attack before they were started on allopurinol treatment, and the existing treatment was continued for another 3 months after the serum uric acid value dropped below 6.5 mg/dL.…”

Section: Discussionmentioning

confidence: 99%

Demographic, clinical, and laboratory features of Turkish patients with gouty arthritis: A prospective cohort study

et al. 2019

View full text Add to dashboard Cite

Objective We have conducted this study to evaluate clinical and laboratory findings and to gather and evaluate information that would be useful in clinical practice, such as demographics, joint involvement patterns, laboratory anomalies, treatments applied, and responses obtained in patients diagnosed with gout. Methods In our study, the demographic, clinical, and laboratory characteristics of 94 patients diagnosed with gout were evaluated. The patients were re-evaluated with regard to their clinical and laboratory findings at the end of the 1 st and 3 rd months, their responses to the treatment were observed, and where necessary, new treatment adjustments were made. Results Seventy-nine (84%) of the patients were men, and 15 (16%) were women. The ages of the patients ranged between 22 and 86 years with the average age being 57.5 years. The joint involvement during a gouty arthritis attack was most frequently observed in the 1st metatarsophalangeal joint (87.2%), followed by the ankle joint (26.9%), and the knee joint (23.7%). The joint involvement pattern was evaluated to reveal that the acute monoarticular arthritis was observed in 87 patients (93.5%), followed by acute oligoarticular arthritis coming in second in terms of frequency (26.9%). An average attack was determined to last 10.7 days, and the average number of attacks in a year was 2.69. In our study, the colchicine treatment in 24 of our patients, in whom it was determined during the admission and follow-up process that they have not had gouty arthritis attack in the past 3 months, was stopped. Five (20.8%) patients whose colchicine treatment was stopped later developed gouty arthritis attacks, and the colchicine treatment was restarted. On the other hand, 10 out of 38 patients (26.3%), who have either been continuing or had never been on colchicine treatment, were observed to experience a gouty arthritis attack during their 1st and 3rd month check-ups. Conclusion In patients with gout, it is recommended that the related diseases, as well as the triggering factors (alcohol, drug use, and dietary effect), be determined, the necessary lifestyle changes be made, and the treatments started.

show abstract

Emodinol ameliorates urate nephropathy by regulating renal organic ion transporters and inhibiting immune inflammatory responses in rats

Zhou

Guo

et al. 2017

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Urate Transporters: Transforming the Face of Hyperuricemia and Gout

Cited by 5 publications

References 15 publications

Kaempferol suppresses inflammation in mice suffering from both hyperuricemia and gouty arthritis through inhibiting NLRP3 inflammasome and NF-κB pathway

Kaempferol suppresses inflammation in mice suffering from both hyperuricemia and gouty arthritis through inhibiting NLRP3 inflammasome and NF-κB pathway

Demographic, clinical, and laboratory features of Turkish patients with gouty arthritis: A prospective cohort study

Emodinol ameliorates urate nephropathy by regulating renal organic ion transporters and inhibiting immune inflammatory responses in rats

Contact Info

Product

Resources

About